Abstract
Previous in-vitro data pointed out lithium, an
activator of the b-catenin signalling pathway, as a
modulator of HIV-1 transcription. We assessed the
effect of in-vivo administration of lithium on viral
latency modulation in nine antiretroviral therapy
(ART)-suppressed HIV-1-infected individuals. We
found that lithium carbonate ...»»»»
Previous in-vitro data pointed out lithium, an
activator of the b-catenin signalling pathway, as a
modulator of HIV-1 transcription. We assessed the
effect of in-vivo administration of lithium on viral
latency modulation in nine antiretroviral therapy
(ART)-suppressed HIV-1-infected individuals. We
found that lithium carbonate treatment was able to
transiently repress HIV-1 residual expression in
CD4R T cells in vivo, which led to a concomitant
short-term decrease in the proviral reservoir size.^^^^
Citation:
Puertas, M. C., Salgado, M., López, S. M., Ouchi, D., Muñoz-Moreno, J. A., Moltó, J., et al. (2014). Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. Aids, 28(14), 2157-2159. 10.1097/QAD.0000000000000373